# US 2021/0276993 A1 · Crystal forms of thiazole compound and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276993 A1
- Document ID: US20210276993A1
- Status: Published application
- Kind: A1
- Application number: 17/258,011
- Filed: 2019-07-05
- Published: 2021-09-09
- Earliest claimed: 2018-07-06
- Assignees: Medshine Discovery Inc.
- Applicants: Medshine Discovery Inc.
- Inventors: Weihua SHI; Zhigan JIANG; Haiying HE
- Web page: https://patentgrep.com/patent/US20210276993A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 31/22: for herpes viruses
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed by the present invention are a crystal form A of a compound represented by formula (I), a compound represented by formula (II) and a crystal form B thereof, as well as an application of the crystal form A of the compound represented by formula (I), the compound represented by formula (II) and the crystal form B thereof in the preparation of a drug for the treatment diseases associated with the herpes simplex virus.

## Claims

### Claim 1

A crystal form A of compound of formula (I), wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 10.81±0.2°, 15.97±0.2°, and 21.69±0.2°,

### Claim 2 (depends on 1)

The crystal form A according to claim 1, wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 10.81±0.2°, 13.03±0.2°, 15.97±0.2°, 18.48±0.2°, 21.69±0.2°, 23.78±0.2°, 25.14±0.2°, and 26.96±0.2°.

### Claim 3 (depends on 2)

The crystal form A according to claim 2, wherein the XRPD pattern thereof is shown in FIG. 1.

### Claim 4 (depends on 1)

The crystal form A according to claim 1, wherein the differential scanning calorimetry curve thereof has a starting point of the endothermic peak at 216.04±3° C.

### Claim 5 (depends on 4)

The crystal form A according to claim 4, wherein the DSC curve thereof is shown in FIG. 2.

### Claim 6 (depends on 1)

The crystal form A according to claim 1, wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.4442% at 120±3° C. and up to 2.4492% at 204±3° C.

### Claim 7 (depends on 6)

The crystal form A according to claim 6, wherein the TGA curve thereof is shown in FIG. 3.

### Claim 8

A compound of Formula (II).

### Claim 9

A crystal form B of a compound of formula (II),
wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 10.17±0.2°, 11.85±0.2°, and 15.94±0.2°.

### Claim 10 (depends on 9)

The crystal form B according to claim 9, wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 8.46±0.2°, 10.17±0.2°, 11.85±0.2°, 13.98±0.2°, 15.94±0.2°, 20.39±0.2°, 21.32±0.2°, and 23.78±0.2°.

### Claim 11 (depends on 10)

The crystal form B according to claim 10, wherein the XRPD pattern thereof is shown in FIG. 4.

### Claim 12 (depends on 9)

The crystal form B according to claim 9, wherein the differential scanning calorimetry curve thereof has a starting point of the endothermic peak at 185.89±3° C.

### Claim 13 (depends on 12)

The crystal form B according to claim 12, wherein the DSC curve thereof is shown in FIG. 5.

### Claim 14 (depends on 9)

The crystal form B according to claim 9, wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.7160% at 187.16±3° C.

### Claim 15 (depends on 14)

The crystal form B according to claim 14, wherein the TGA curve thereof is shown in FIG. 6.

### Claim 16 (depends on 1)

A method of treating a disease related to herpes simplex virus in a subject in need thereof, comprising administering to the subject the crystal form A of the compound of formula (I) according to claim 1.

### Claim 17 (depends on 8)

A method of treating a disease related to herpes simplex virus in a subject in need thereof, comprising administering to the subject the compound of formula (II) according to claim 8.

### Claim 18 (depends on 9)

A method of treating a disease related to herpes simplex virus in a subject in need thereof, comprising administering to the subject the crystal form B of the compound of formula (II) according to claim 9.

### Claim 19 (depends on 4)

The crystal form A according to claim 4, wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.4442% at 120±3° C. and up to 2.4492% at 204±3° C.

### Claim 20 (depends on 12)

The crystal form B according to claim 12, wherein the thermogravimetric analysis curve thereof has a weight loss of up to 0.7160% at 187.16±3° C.